Serum level of soluble receptor for advanced glycation end products in asthmatic children and its correlation to severity and pulmonary functions

Clinical Laboratory

Volumn 60, Issue 6, 2014, Pages 957-962

  El Seify, Magda Y Hussein ^a   Fouda, Eman Mahmoud ^a   Nabih, Enas Samir ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Asthma control; Sputum neutrophilia; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NEUTROPHIL COUNT; PHENOTYPE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEVERE PERSISTENT ASTHMA; SPUTUM CYTODIAGNOSIS; STATISTICAL SIGNIFICANCE; TOTAL LUNG CAPACITY;

ASTHMA; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; RECEPTORS, IMMUNOLOGIC; ROC CURVE;

EID: 84903754505     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130418     Document Type: Article

References (15)

1. WHO Chronic Respiratory Diseases. World Health Organization Reviewed ; 2010.
2. Hossny EM, Hasan ZE, Allam MF, Mahmoud ES. Analysis of the filed data of a sample of Egyptian children with bronchial asthma. Egypt J Pediatr Allergy Immunol 2009;7:59-64.
3. Fahy JV. Eosinophilic and Neutrophilic inflammation in asthma. Proc Am Thorac 2009;6:256-9.
4. Santilli F, Vazanna N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: Clinical and therapeutically implications. Current Medical Chemistry 2009;16:940-52.
5. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respiratory Research 2011;30:12-37.
6. Global Initiative for Asthma [GINA], GINA Report, Global Strategy for Asthma Managementand Prevention; 2008.
7. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
8. Fahy JV, Boushey HA, Lazarus SC, et al; NHLBI Asthma Clinical Research Network. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 2001;163:1470-5. (Pubitemid 32506618)
9. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010;125:1028-36.
10. Sukkar MB, Wood LG, Tooze M, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012;39: 721-9.
11. Kumano-Kuramochi M, Ohnishi-Kameyama M, Xie Q, et al. Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem Biophys Res Commun 2009;386:130-4.
12. Koch M, Chitayat S, Dattilo BM, et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010;18:1342-52.
13. Candia LD, Saunders R, Brightling CE. The RAGE against the storm. Eur Respir J 2012;39:515-7.
14. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end products in COPD. Eur Respir J 2011;37:516-22.
15. Yijie W, Hongmei W, Melissa G, et al sRAGE induces human monocyte survival and differentiation. Journal of Immunology 2010;185:1822-35.